Irinotecan liposomes for high-grade neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a high-grade (grade 3) neuroendocrine tumor or neuroendocrine cancer in the digestive system.
- You have not had systemic cancer treatment before, or you have had it but it's not working anymore.
- You have at least one measurable tumor that appears on a CT scan.
- You are in generally good health, with adequate blood counts, liver and kidney function.
- You are willing to use contraception if you are of childbearing age and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) in people whose advanced neuroendocrine carcinoma has stopped responding to standard first-line treatment. The goal is to see if this special formulation can help slow or shrink the cancer.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a new combination treatment with irinotecan liposome for advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line therapy. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial tests a new combination of drugs as the first treatment for people with advanced neuroendocrine cancer of the digestive system that has spread. It aims to see if the combination can shrink tumors and help people live longer.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.